MIROCALS clinical trial
Testing the effects of low-dose interleukin-2 on disease progression and survival
MIROCALS (Modifying Immune Response and Outcomes in ALS) is a joint clinical trial between clinicians in France and the UK that will test a molecule that occurs naturally in our bodies called interleukin-2 (IL-2) as a potential new therapy for MND. This trial will test the effectiveness and safety of a low dose of IL-2 in people with MND, to find out what effects, good or bad, it has on people with MND and, in particular, if it may slow down the advance of the disease.
What does taking part involve?
After being assessed for eligibility, you would start receiving riluzole for three months (if you were already taking riluzole before the study began, you will first have a one month ‘wash-out’ period without riluzole). You will then begin to receive treatment injections (either IL-2 or placebo) that you will give yourself once a day for five days every 4 weeks (total of 19 5-day cycles). Throughout the 18-month period you will be asked to visit the clinic every 2-3 months for routine checks of your symptoms. At some of these visits you will also be asked to provide samples of blood and cerebrospinal fluid.
Brighton (Royal Sussex County Hospital), Glasgow (Queen Elizabeth University Hospital), London (King’s College Hospital, Royal London Hospital, and National Hospital for Neurology and Neurosurgery), Manchester (Royal Salford Hospital), Sheffield (Royal Hallamshire Hospital).
Who can take part?
People living with ALS, who:
• are less than 24 months since symptom onset, and
• haven't been treated with riluzole, or, been taking riluzole for less than 1 month.
How do I take part?
If you think you may be eligible, you should speak to your neurologist to refer you to one of the recruitment centres.
This trial is funded by the European Union’s Horizon 2020 research and innovation programme (No. 633413) and the MND Association.
Expiry date: N/A